Clinical Trial

Critical Care Outcomes of Hematologic Oncology Patients

Study acronym: COHO
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 27, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Hematologic malignancy patients are admitted to ICU in increasing numbers. Successful ICU intervention has led to an increasing number of ICU survivors; however, there is a lack of information available about these patients' long term survival and quality of life. There is little Canadian data regarding ICU survival and regarding 1-year survival and functional outcomes in this group of patients. Over 500 patients are admitted annually to Canadian ICUs with an underlying hematologic malignancy or stem cell transplant, yet there is a paucity of up to date long-term outcome data. This information will facilitate a better understanding who would best benefit from critical care interventions and the impact of critical illness on their level of function at 1 year as well as survival.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2018-02-22; most recent amendment 2024-11-25.
Status change: Recruiting → Active, Not Recruiting 2021-09-03
Status change: Not Yet Recruiting → Recruiting 2018-03-20
Trial Details
NCT Number NCT03449953
Lead Sponsor Mount Sinai Hospital, Canada
Conditions Hematologic Malignancy, Stem Cell Transplant
Enrollment 415 participants
Start Date 2018-02-26
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-27